These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19387707)

  • 81. [Screening for Staphylococcus aureus with a reduced susceptibility to vancomycin in: a Belgian hospital].
    Piérard D; Vandenbussche H; Verschraegen I; Lauwers S
    Pathol Biol (Paris); 2004 Oct; 52(8):486-8. PubMed ID: 15465269
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital.
    Sancak B; Ercis S; Menemenlioglu D; Colakoglu S; Hasçelik G
    J Antimicrob Chemother; 2005 Sep; 56(3):519-23. PubMed ID: 16046461
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland.
    Krzysztoń-Russjan J; Gniadkowski M; Połowniak-Pracka H; Hagmajer E; Hryniewicz W
    J Antimicrob Chemother; 2002 Dec; 50(6):1065-9. PubMed ID: 12461035
    [TBL] [Abstract][Full Text] [Related]  

  • 84. In vitro synergistic effects of various combinations of vancomycin and non-beta-lactams against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Kang YR; Chung DR; Kim J; Baek JY; Kim SH; Ha YE; Kang CI; Peck KR; Song JH
    Diagn Microbiol Infect Dis; 2016 Nov; 86(3):293-299. PubMed ID: 27591174
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea.
    Park JW; Lee H; Kim JW; Kim B
    Sci Rep; 2019 Apr; 9(1):6236. PubMed ID: 30996231
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections.
    Kopp BJ; Nix DE; Armstrong EP
    Ann Pharmacother; 2004 Sep; 38(9):1377-82. PubMed ID: 15266044
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin.
    Ward PB; Johnson PD; Grabsch EA; Mayall BC; Grayson ML
    Med J Aust; 2001 Nov; 175(9):480-3. PubMed ID: 11758077
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Comparative proteomics-based identification of genes associated with glycopeptide resistance in clinically derived heterogeneous vancomycin-intermediate Staphylococcus aureus strains.
    Chen H; Liu Y; Zhao C; Xiao D; Zhang J; Zhang F; Chen M; Wang H
    PLoS One; 2013; 8(6):e66880. PubMed ID: 23840544
    [TBL] [Abstract][Full Text] [Related]  

  • 89. In vivo efficacy and pharmacological properties of a novel glycopeptide (YV4465) against vancomycin-intermediate Staphylococcus aureus.
    Yarlagadda V; Konai MM; Paramanandham K; Nimita VC; Shome BR; Haldar J
    Int J Antimicrob Agents; 2015 Oct; 46(4):446-50. PubMed ID: 26188396
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus.
    Zheng X; Berti AD; McCrone S; Roch M; Rosato AE; Rose WE; Chen B
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158272
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Methicillin-resistant
    Lin CY; Wang JH; Lin KH; Ho YL; Ho CM
    Ci Ji Yi Xue Za Zhi; 2018; 30(3):135-140. PubMed ID: 30069120
    [No Abstract]   [Full Text] [Related]  

  • 92. Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia.
    Chong YP; Park KH; Kim ES; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Kim YS
    Antimicrob Agents Chemother; 2015; 59(6):3541-7. PubMed ID: 25845875
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant Staphylococcus aureus: A first report from South India.
    Bakthavatchalam YD; Babu P; Munusamy E; Dwarakanathan HT; Rupali P; Zervos M; John Victor P; Veeraraghavan B
    PLoS One; 2019; 14(12):e0227009. PubMed ID: 31887179
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients.
    Koh YR; Kim KH; Chang CL; Yi J
    Ann Lab Med; 2016 May; 36(3):235-43. PubMed ID: 26915612
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Is prediffusion test an alternative to improve accuracy in screening hVISA strains and to detect susceptibility to glycopeptides/lipopeptides?
    Silveira AC; Sambrano GE; Paim TG; Caierão J; Cordova CM; d'Azevedo PA
    Diagn Microbiol Infect Dis; 2014 Aug; 79(4):401-4. PubMed ID: 24906792
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus.
    Ruef C
    Infection; 2004 Dec; 32(6):315-27. PubMed ID: 15597220
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Reduced Susceptibility and Resistance to Vancomycin of Staphylococcus aureus: A Review of Global Incidence Patterns and Related Genetic Mechanisms.
    Unni S; Siddiqui TJ; Bidaisee S
    Cureus; 2021 Oct; 13(10):e18925. PubMed ID: 34812309
    [No Abstract]   [Full Text] [Related]  

  • 98. Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections.
    Holmes NE; Johnson PD; Howden BP
    J Clin Microbiol; 2012 Aug; 50(8):2548-52. PubMed ID: 22593595
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Antimicrobial susceptibility and genetic features of a heterogeneous vancomycin intermediate-resistant Staphylococcus aureus strain.
    Wan L; Ye C; Li B; Soteyome T; Bao X; Lu Z; Xu W; Mao Y; Li L; Chen D; Yang L; Xu Z; Harro J
    Infect Genet Evol; 2020 Nov; 85():104565. PubMed ID: 32971249
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Vancomycin: the tale of the vanquisher and the pyrrhic victory.
    De Vriese AS; Vandecasteele SJ
    Perit Dial Int; 2014; 34(2):154-61. PubMed ID: 24676741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.